{"entity":{"id":"nct06710158","kind":"trial","name":"Study of SC-102 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of SC-102 run by Tianjin ConjuStar Biologics Co., Ltd., now recruiting.","summary":"Study of SC-102 in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT06710158 by Tianjin ConjuStar Biologics Co., Ltd., with 120 participants planned, started 2024-12-05. Conditions recorded: Advanced Solid Cancers. Interventions recorded: SC-102.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06710158","url":"https://clinicaltrials.gov/study/NCT06710158"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["sc-102"],"companies":["conjustar-biologics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06710158","phase":"1","setting":"Phase Ⅰ Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of SC-102 in Subjects With Advanced or Metastatic Solid Tumors That Express EphA2","sponsor":"Tianjin ConjuStar Biologics Co., Ltd.","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06710158/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"sc-102","kind":"drug","name":"SC-102","route":"/drugs/sc-102/"}],"company":[{"id":"conjustar-biologics","kind":"company","name":"ConjuStar Biologics","route":"/companies/conjustar-biologics/"}]}}